



Myeloperoxidase Peroxidation Fluorometric Assay Kit

Item No. 700160

www.caymanchem.com
Customer Service 800.364.9897
Technical Support 888.526.5351
1180 E. Ellsworth Rd · Ann Arbor, MI · USA

TABLE OF CONTENTS

GENERAL INFORMATION	3	Materials Supplied
	4	Safety Data
	4	Precautions
	4	If You Have Problems
	5	Storage and Stability
	5	Materials Needed but Not Supplied
INTRODUCTION	6	Background
	7	About This Assay
PRE-ASSAY PREPARATION	8	Reagent Preparation
	9	Sample Preparation
ASSAY PROTOCOL	10	Plate Set Up
	12	Standard Preparation
	13	Performing the Assay
ANALYSIS	15	Calculations
	18	Performance Characteristics
RESOURCES	19	Interferences
	20	Troubleshooting
	21	References
	22	Plate Template
	23	Notes
	23	Warranty and Limitation of Remedy

GENERAL INFORMATION

Materials Supplied

This kit will arrive packaged as a 4°C kit. After opening the kit, store individual components as stated below.

Item Number	Item	Quantity	Storage
700164	MPO Assay Buffer	1 bottle	4°C
700023	Resorufin Standard	500 µl	-20°C
700001	DMSO Assay Reagent	1 ml	RT
700168	MPO Hydrogen Peroxide	1 vial	4°C
700166	Myeloperoxidase Assay Reagent	1 vial	-20°C
700167	MPO Inhibitor	1 vial	4°C
700002	ADHP Assay Reagent	5 vials	-20°C
400017	96-Well Solid Plate (black)	2 plates	RT
400012	96-Well Cover Sheets	2 covers	RT

If any of the items listed above are damaged or missing, please contact our Customer Service department at (800) 364-9897 or (734) 971-3335. We cannot accept any returns without prior authorization.



WARNING: THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Safety Data

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

Precautions

Please read these instructions carefully before beginning this assay.

If You Have Problems

Technical Service Contact Information

Phone: 888-526-5351 (USA and Canada only) or 734-975-3888
Fax: 734-971-3640
Email: techserv@caymanchem.com

In order for our staff to assist you quickly and efficiently, please be ready to supply the lot number of the kit (found on the outside of the box).

Storage and Stability

This kit will perform as specified if stored as directed in the **Materials Supplied** section on page 3 and used before the expiration date indicated on the outside of the box.

Materials Needed But Not Supplied

1. A plate reader with the ability to measure fluorescence using an excitation wavelength of 530-540 nm and an emission wavelength of 585-595 nm
2. Adjustable pipettes and a multichannel or repeating pipette
3. A source of pure water; glass distilled water or HPLC-grade water is acceptable

Background

Myeloperoxidase (MPO) is a heme-containing enzyme and the most abundant protein in polymorphonuclear leukocytes (PMNs).¹ It is composed of two subunits linked by a disulfide bridge with each subunit containing a light and heavy polypeptide chain. MPO is stored in azurophilic granules of PMNs and is released from activated or necrotic PMNs, after which it can bind to and modify acidic serum proteins, as well as recruit additional PMNs.¹ It can oxidize a variety of substrates and catalyzes the formation of highly reactive (pseudo)hypochlorous acids and radicals, including hypochlorous acid (HOCl), using hydrogen peroxide (H_2O_2) for chlorination or peroxidation.¹ The use of H_2O_2 by MPO for either its chlorination or peroxidation activities depends on the relative concentrations of chloride and the reducing substrate.² MPO also has roles in PMN apoptosis and antimicrobial defense systems, including neutrophil extracellular trap (NET) formation and NETosis.^{1,3,4} It enhances neutrophil elastase-induced chromatin decondensation and produces reactive oxygen species (ROS), which trigger NET formation.⁵ MPO-derived oxidants and chlorinated products are enriched in LDL and human atherosclerotic lesions.⁶⁻⁸ In addition, MPO levels in leukocytes and the blood are elevated in patients with coronary artery disease (CAD), and elevated serum levels of MPO in patients with acute coronary syndromes are considered a risk factor for subsequent cardiovascular events.⁷⁻⁹

About This Assay

Cayman's MPO Peroxidation Fluorometric Assay provides a convenient fluorescence-based method for detecting the MPO peroxidase activity in both crude cell lysates and purified enzyme preparations. The assay utilizes the peroxidase component of MPO, where a single two electron oxidation of native enzyme (MPO) to compound I (MPO-I) is followed by two successive one electron reductions back to native enzyme by compound II (MPO-II).⁷ The reaction between hydrogen peroxide and ADHP (10-acetyl-3,7-dihydroxyphenoxazine) produces the highly fluorescent compound resorufin (See Figure 1). Resorufin fluorescence can be easily analyzed with an excitation wavelength of 530-540 nm and emission wavelength of 585-595 nm. The kit includes a MPO-specific inhibitor for distinguishing between MPO activity from MPO-independent fluorescence.




Figure 1. Assay scheme

Reagent Preparation

1. MPO Assay Buffer - (Item No. 700164)

This bottle contains 50 ml of 1X Assay Buffer, pH 7.4. It is ready to use in the assay.

2. Resorufin Standard - (Item No. 700023)

This vial contains 500 µl of a 2 mM solution of resorufin. The reagent is ready to use to prepare the resorufin standard curve.

3. DMSO Assay Reagent - (Item No. 700001)

This vial contains 1 ml of dimethylsulfoxide (DMSO). The reagent is ready to use as supplied.

4. MPO Hydrogen Peroxide - (Item No. 700168)

This vial contains 100 µl of a 30% solution of hydrogen peroxide. Prior to assaying, mix 10 µl with 90 µl of MPO Assay Buffer to yield a 3% solution. Then mix 10 µl of the 3% solution with 1.74 ml of MPO Assay Buffer to prepare a 5 mM solution. The 5 mM solution will be used to prepare the Initiator Solution. The diluted solutions are stable for two hours.

5. Myeloperoxidase Assay Reagent - (Item No. 700166)

This vial contains 50 µl of a 100 µg/ml solution of human polymorphonuclear leukocyte MPO. Thaw and store the enzyme on ice while preparing the reagents for the assay. Prior to assaying, pipette up and down to mix thoroughly because this enzyme settles over time. Mix 25 µl of MPO with 1975 µl of MPO Assay Buffer for a final MPO concentration of 1.25 µg/ml. The diluted enzyme is stable for one hour on ice.

6. MPO Inhibitor - (Item No. 700167)

This vial contains 300 µl of 50 mM 4-aminobenzhydrazide, a MPO inhibitor.^{8,9} Prior to assaying, mix 10 µl of Inhibitor with 490 µl of MPO Assay Buffer. This is enough Inhibitor to assay 50 wells. The diluted Inhibitor is stable for four hours.

7. MPO Peroxidation Substrate

Immediately prior to preparing the Initiator Solution, add 120 µl of DMSO Assay Reagent (Item No. 700001) to one vial of ADHP Assay Reagent (Item No. 700002) and vortex until dissolved. Then add 470 µl of MPO Assay Buffer for a final MPO Peroxidation Substrate concentration of 1 mM. This is enough MPO Peroxidation Substrate to assay 100 wells. Prepare additional vials as needed. The reconstituted MPO Peroxidation Substrate stable for 15 minutes. After 15 minutes, increased background fluorescence will occur.

Sample Preparation

The kit is designed for detection of MPO activity in cell lysates and in purified solutions. This assay is not compatible for use with serum samples. Some reagents have been shown to interfere with this assay, see page 19 for a list of compatible reagents.

Cell Lysate

1. Collect cells ($\sim 7 \times 10^6$) by centrifugation (*i.e.*, 1,000-2,000 x g for 10 minutes at 4°C). For adherent cells, do not harvest using proteolytic enzymes; rather use a rubber policeman.
2. Sonicate cell pellet in 0.5-1 ml of cold 1X PBS, pH 7.4, on ice.
3. Centrifuge at 10,000 x g for 10 minutes at 4°C.
4. Remove the supernatant and store on ice.
5. We recommend assaying for MPO activity on the same day of collection. If this is not possible, freeze the sample at -80°C. The sample will be stable for at least one week.

Plate Set Up

There is no specific pattern for using the wells on the plate. However, a resorufin standard curve in duplicate has to be assayed with two wells for the sample and the MPO positive control. We suggest that each sample be assayed at least in duplicate. It is also recommended to assay each sample in the presence and absence of the MPO Inhibitor to allow for the correction of non-MPO-independent fluorescence and to record the contents of each well on the template sheet provided on page 22. A typical layout of samples to be measured in duplicate is shown below in Figure 2.

	1	2	3	4	5	6	7	8	9	10	11	12
A	(A)	(A)	(+)	(+)	(I4)	(I4)	(I8)	(I8)	(I12)	(I12)	(I16)	(I16)
B	(B)	(B)	(S1)	(S1)	(S5)	(S5)	(S9)	(S9)	(S13)	(S13)	(S17)	(S17)
C	(C)	(C)	(I1)	(I1)	(I5)	(I5)	(I9)	(I9)	(I13)	(I13)	(I17)	(I17)
D	(D)	(D)	(S2)	(S2)	(S6)	(S6)	(S10)	(S10)	(S14)	(S14)	(S18)	(S18)
E	(E)	(E)	(I2)	(I2)	(I6)	(I6)	(I10)	(I10)	(I14)	(I14)	(I18)	(I18)
F	(F)	(F)	(S3)	(S3)	(S7)	(S7)	(S11)	(S11)	(S15)	(S15)	(S19)	(S19)
G	(G)	(G)	(I3)	(I3)	(I7)	(I7)	(I11)	(I11)	(I15)	(I15)	(I19)	(I19)
H	(H)	(H)	(S4)	(S4)	(S8)	(S8)	(S12)	(S12)	(S16)	(S16)	()	()

A-H = Resorufin Standards
 + = MPO Positive Control
 S = Sample Wells
 I = Sample + Inhibitor Wells

Figure 2. Sample plate format

Pipetting Hints

- It is recommended that a multichannel pipette be used to deliver reagents to the wells. This saves time and helps to achieve more precise incubation times.
- Before pipetting each reagent, equilibrate the pipette tip in that reagent (*i.e.*, slowly fill the tip and gently expel the contents, repeat several times).
- Do not expose the pipette tip to the reagent(s) already in the well.

General Information

- The final volume of the assay is 110 μ l in all the wells.
- All reagents except the enzymes must be equilibrated to room temperature before beginning the assay.
- It is not necessary to use all the wells on the plate at one time.
- We recommend assaying samples in triplicate, but it is the user's discretion to do so.
- The assay is performed at room temperature.
- Monitor the fluorescence with an excitation wavelength of 530-540 nm and an emission wavelength of 585-595 nm.

Standard Preparation

Mix 50 μl of the Resorufin Standard with 150 μl of MPO Assay Buffer to yield a concentration of 500 μM . Mix 20 μl of this 500 μM standard with 980 μl of MPO Assay Buffer to yield a stock concentration of 10 μM . Add the amount of Resorufin Standard (10 μM) and MPO Assay Buffer to each well of a dilution plate (or microcentrifuge tube) as described in Table 1. The diluted standards are stable for four hours at room temperature.

Well (or Tube)	10 μM Resorufin Standard (μl)	MPO Assay Buffer (μl)	Final Concentration (μM)
A	0	200	0
B	5	195	0.25
C	10	190	0.5
D	20	180	1
E	40	160	2
F	100	100	5
G	160	40	8
H	200	0	10

Table 1. Preparation of the Resorufin Standards

Performing the Assay

1. **Standard Wells** - add 60 μl of MPO Assay Buffer and 50 μl of Standard (wells or tubes, A-H) per well in the designated wells on the plate (see Sample plate format, Figure 2, page 10).
2. Read the plate in a plate reader using an excitation wavelength of 530-540 nm and an emission wavelength of 585-595 nm. This will allow you to establish an appropriate *gain* for detecting the entire range of the standards. This *gain* will then be used when assaying the samples.
3. In a suitable tube, prepare the Initiator Solution according to the table below:

Reagents	50 wells	100 wells	150 wells	200 wells
MPO Assay Buffer	2.24 ml	4.48 ml	6.72 ml	8.96 ml
MPO Peroxidation Substrate (1 mM)	250 μl	500 μl	750 μl	1 ml
Hydrogen Peroxide (5 mM)	10 μl	20 μl	30 μl	40 μl

Table 2. Initiator Solution Preparation

- MPO Positive Control Wells - add 50 µl of MPO Assay Buffer and 10 µl of 1.25 µg/ml Myeloperoxidase Assay Reagent to two wells.
- Sample Wells** - add 50 µl of MPO Assay Buffer and 10 µl of experimental sample to two wells. To obtain reproducible results, the amount of myeloperoxidase added to the wells should fall within the range of the assay. When necessary, samples should be diluted with MPO Assay Buffer or concentrated with a centrifugal concentrator with a molecular weight cut-off of 30 kDa to bring the enzymatic activity to this level.
- Inhibitor Wells** - add 40 µl of MPO Assay Buffer, 10 µl of diluted MPO Inhibitor, and 10 µl of sample to two wells.

Well Type	MPO Assay Buffer	Myeloperoxidase Assay Reagent (1.25 µg/ml)	Sample	MPO Inhibitor
Positive Control	50 µl	10 µl	-	-
Sample	50 µl	-	10 µl	-
Inhibitor	40 µl	-	10 µl	10 µl

Table 3. Pipetting Summary

- Begin the reactions by quickly adding 50 µl of the Initiator Solution to the positive control, sample, and inhibitor wells.
- Read the plate in a plate reader every 30 seconds for 15 minutes using an excitation wavelength of 530-540 nm and emission wavelength of 585-595 nm.

ANALYSIS

Calculations

Plot the Standard Curve

- Determine the average fluorescence of the standards. Subtract the fluorescence value of the standard A from itself and all other standards. This is the corrected fluorescence.
- Plot the corrected fluorescence values (from step 1 above) of each standard as a function of the final concentration of resorufin from Table 1. See Figure 3, on page 16, for a typical standard curve.

Determine MPO Activity

- Determine the average fluorescence of each sample and sample plus inhibitor.
- Determine the change in fluorescence (RFU) per minute for the sample and sample plus inhibitor by:
 - Plotting the fluorescence values as a function of time to obtain the slope (rate) of the linear portion of the curve. An example of human polymorphonuclear leukocyte MPO assayed with and without MPO inhibitor over time is shown in Figure 4, on page 17.

OR

 - Select two points on the linear portion of the curve and determine the change in fluorescence during that time using the following equation:

$$\text{RFU/min} = \frac{\text{RFU (Time 2)} - \text{RFU (Time 1)}}{\text{Time 2 (min)} - \text{Time 1 (min)}}$$

3. Calculate the MPO activity using the equation below. One unit is defined as the amount of enzyme that will cause the formation of 1 nmol of fluorophore per minute at 25°C.

Myeloperoxidase Activity (nmol/min/ml) =

$$\frac{\text{Sample slope (RFU/min)} - \text{Inhibitor slope (RFU/min)}}{\text{Resorufin standard curve slope (RFU/}\mu\text{M)}} \times \text{Sample dilution}$$

Sample Data:

The data shown here is an example of the data typically produced with this kit. Your results may vary, and therefore should not be directly compared to these samples.




Figure 3. Resorufin Standard Curve




Figure 4. Human polymorphonuclear leukocyte MPO assayed with and without MPO inhibitor.

Performance Characteristics

Precision:

When a series of sixteen MPO measurements were performed on the same day, the intra-assay coefficient of variation was 2.8%. When a series of sixteen MPO measurements were performed on five different days under the same experimental conditions, the inter-assay coefficient of variation was 3.12%.

Assay Range:

Under the standardized conditions of the assay described in this booklet, the dynamic range of the kit is 0-10 μM of resorufin.

RESOURCES

Interferences

The following reagents were tested in the assay for interference in the assay:

	Reagent	Will Interfere (Yes or No)
Buffers	Tris	No
	HEPES	Yes
	Phosphate	No
Detergents	Polysorbate 20 (0.1%)	Yes
	Polysorbate 20 (1%)	Yes
	Triton X-100 (0.1%)	Yes
	Triton X-100 (1%)	Yes
Protease Inhibitors/ Chelators/Enzymes	EDTA (1 mM)	No
	EGTA (1 mM)	No
	Trypsin (10 $\mu\text{g}/\text{ml}$)	No
	PMSF (1 mM)	Yes
	Leupeptin (10 $\mu\text{g}/\text{ml}$)	No
	Antipain (10 $\mu\text{g}/\text{ml}$)	No
	Chymostatin (10 $\mu\text{g}/\text{ml}$)	No
Solvents	Ethanol (10 μl)	No
	Methanol (10 μl)	No
	Dimethylsulfoxide (10 μl)	Yes
Others	BSA (0.1%)	Yes
	Glutathione (1 mM)	Yes
	Glycerol (5%)	No

Troubleshooting

Problem	Possible Causes	Recommended Solutions
Erratic values; dispersion of duplicates/triplicates	A. Poor pipetting/technique B. Bubble in the well(s)	A. Be careful not to splash the contents of the wells B. Carefully tap the side of the plate with your finger to remove bubbles
No fluorescence detected in the sample wells	Sample was too dilute	A. Re-assay the sample using a lower dilution B. Concentrate the sample with a centrifugal concentrator with a 30 kDa cut-off
The plate reader exhibited 'MAX' values for the wells	The gain setting is too high	A. Reduce the gain and re-read B. Make sure to establish the gain using the resorufin standards before assaying your samples
No inhibition was seen with the MPO inhibitor	A. MPO activity is too low to detect B. The sample does not contain MPO C. Sample contains something that is interfering with the assay	A. Re-assay the sample using a lower dilution B. Check the interference section for possible interfering reagents (see page 19)

References

1. Arnhold, J. and Flemmig, J. Human myeloperoxidase in innate and acquired immunity. *Arch. Biochem. Biophys.* **500(1)**, 92-106 (2010).
2. Kettle, A.J. and Winterbourn, C.C. Assays for the chlorination activity of myeloperoxidase. *Methods Enzymol.* **233**, 502-512 (1994).
3. Metzler, K.D., Fuchs, T.A., Nauseef, W.M., *et al.* Myeloperoxidase is required for neutrophil extracellular trap formation: Implications for innate immunity. *Blood* **117(3)**, 953-959 (2011).
4. Urban, C.F., Ermert, D., Schmid, M., *et al.* Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against *Candida albicans*. *PLoS Pathogens* **5(10)**, e1000639 (2009).
5. Kumar, S., Gupta, E., Kaushik, S., *et al.* Neutrophil extracellular traps: Formation and involvement in disease progression. *Iran J. Allergy Asthma Immunol.* **17(3)**, 208-220 (2018).
6. Podrez, E.A., Abu-Soud, H.M., and Hazen, S.L. Myeloperoxidase-generated oxidants and atherosclerosis. *Free Radic. Biol. Med.* **28(12)**, 1717-1725 (2000).
7. Baldus, S., Heeschen, C., Meinertz, T., *et al.* Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. *Circulation* **108(12)**, 1440-1445 (2003).
8. Malle, E., Furtmüller, P.G., Sattler, W., *et al.* Myeloperoxidase: A target for new drug development? *Br. J. Pharmacol.* **152(6)**, 838-854 (2007).
9. Zhang, R., Brennan, M.L., Fu, X., *et al.* Association between myeloperoxidase levels and risk of coronary artery disease. *JAMA* **286(17)**, 2136-2142 (2001).

1								
2								
3								
4								
5								
6								
7								
8								
9								
10								
11								
12								
	A	B	C	D	E	F	G	H

NOTES

Warranty and Limitation of Remedy

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

This document is copyrighted. All rights are reserved. This document may not, in whole or part, be copied, photocopied, reproduced, translated, or reduced to any electronic medium or machine-readable form without prior consent, in writing, from Cayman Chemical Company.

©02/03/2021, Cayman Chemical Company, Ann Arbor, MI, All rights reserved. Printed in U.S.A.

